Abstract
This case describes a rare occurrence of post-SARS-CoV-2 infection reactive arthritis with psoriasiform lesions. The patient failed to respond to conventional therapies but responded well to secukinumab, underscoring that it may be a valuable treatment for refractory post-SARS-CoV-2 infection reactive arthritis when conventional therapies fail.